United Therapeutics (UTHR) CEO Rothblatt Sells $5.3M of Stock

United Therapeutics Corporation Chairperson and CEO Martine A Rothblatt sold 9,500 shares of stock on October 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at an average price of $553.87, for a total value of about $5.26 million. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

UTHR United Therapeutics Corporation

$562.88 ▲ +13.32% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Martine A Rothblatt's Trade

The planned sale reduced the chief executive's holdings by 2.84%, leaving her with 324,443 shares of the drug maker. On the day of the transaction, United Therapeutics shares closed at $553.88. This trade follows a string of similar planned dispositions by company leadership throughout October.

Other Institutional Activity in United Therapeutics

Large institutional funds have also adjusted their positions in the biotech firm. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.57 billion. Renaissance Technologies, LLC reduced its stake by 78,271 shares, finishing with 1,708,739 shares valued at roughly $962.9 million. Meanwhile, Jupiter Topco LLC doubled its stake with a 100% increase, adding 415,564 shares to hold 831,129 shares worth about $468.3 million.

United Therapeutics Corporation Stock Up 5.7%

Shares recently traded around $553.88 as of October 21, 2026, matching the previous session's close. The stock is trading about 7.6% above its 50-day moving average of $514.75 and sits roughly 9.1% below its 52-week high of $609.35.

Recent Earnings

For the trailing twelve months, United Therapeutics reported revenue of $3.15 billion with earnings of $27.89 per share. The company generated a net profit margin of 41.6% and a return on equity of 19.3%. The next corporate earnings release is scheduled for October 28, 2026.

Dividend

United Therapeutics currently does not pay a dividend, maintaining a payout ratio of 0.0%.

Insider Buying and Selling at United Therapeutics Corporation

Leadership at United Therapeutics has engaged in a series of planned stock sales through October. General counsel Paul A. Mahon sold 8,300 shares on October 15 for roughly $4.52 million. Chief executive Martine A. Rothblatt also executed sales prior to this transaction, disposing of 9,500 shares on October 15 for about $5.19 million, 9,500 shares on October 16 for approximately $5.08 million, and another 9,500 shares on October 19 for about $5.16 million. All of these insider transactions were carried out under pre-arranged plans.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock heading into the fourth quarter. Goldman Sachs initiated coverage with a sell rating and a $321 target on September 24, while BTIG upgraded the stock to a buy with a $728 target on October 1. Morgan Stanley maintained an equal-weight rating while lifting its target to $566 on October 7. RBC Capital kept an outperform rating and raised its target to $708 on October 8. Leerink Partners maintained an outperform rating with a $725 target on October 19. Overall, the stock carries a consensus buy rating from analysts.

About United Therapeutics

United Therapeutics Corporation focuses on developing and commercializing specialty pharmaceutical products for patients dealing with severe, chronic medical conditions. Headquartered in Silver Spring, Maryland, the company targets rare illnesses with specialized therapies in the healthcare sector.

Bottom Line

Investors will look toward the upcoming earnings report on October 28, 2026, for further updates on financial performance and product growth. Monitoring subsequent Form 4 filings will show whether executive sales under trading plans continue through the final quarter.